Educational Materials

Do you need information about Parkinson's? PDF's educational materials provide information about symptoms, medications, local resources and more.
*New Resource List*
The PD Resource List includes over 650 resources to address the needs of people living with PD.
How Private Gifts Can Lead to Public Dollars: One PD Scientist’s Story
Nearly ten years ago, soon after receiving his doctor’s degree, Michael Jakowec received a fellowship from the Parkinson’s Disease Foundation (PDF) to work in the research labs of Dr. Serge Przedborski at Columbia University on Parkinson’s research.
Not long after the fellowship ended, Dr. Jakowec, then based at the Parkinson’s Institute, California, applied to PDF again for support – this time, for one of its International Research Grants. His proposal: to work with the mouse model of Parkinson’s disease to identify proteins responsible for neuroplasticity (the re-growth of injured neurons) and thereby potentially identifying new therapeutic targets for treatment of Parkinson’s disease (PD).
The promising results of this initial study, led Dr. Jakowec - now
an assistant professor at the University of Southern California (USC)
to apply for and receive a second PDF grant in 2000, this one to
help him investigate glutamate-dopamine interactions that may underlie
the mechanism of neuroplasticity in this mouse model. The synergism
between glutamate and dopamine may be critical both for the maintenance
of proper motor function and for brain repair in times of neuronal
injury, such as PD. His studies suggested that if we can understand
the molecular mechanisms responsible for neuroplasticity we have
the means to understand better how these processes work in patients
with PD and other movement disorders.
Dr Jakowec’s results gave us a closer understanding
of the molecular basis of the alteration in proteins, illustrating
the capacity of the brain to repair and rearrange neuronal
connections. This is important for Parkinson’s because
as Dr. Jakowec commented in his report: “since a large
number of dopaminergic neurons remain, even in the later
stages of the disease, this in fact may provide a template
to induce restorative neuroplasticity and consequently reverse
clinical motor symptoms”.
Then came his first triumph as a young research scientist. The data collected as a direct result of the two PDF grants provided a foundation of preliminary data to support a major proposal by Dr. Jakowec to the National Institute of Neurological Disorders and Stroke, the source of most federal funding for the neuro-sciences. His proposal, which placed in the top 10 percent of those competing in that year, resulted in a four-year award of $995,000 to support his work. The first aim of the project, which began last summer, is to define the role of dopamine-glutamate interactions in inducing neuroplasticity in the injured basal ganglia. It will then seek to determine if, and how, surviving neurons are able to spout and branch in injured regions of the brain, thereby compensating for lost neuronal connections.
Dr. Jakowec’s research career to date exemplifies the objectives
of the International Research Grants Program (known as “IRGP”).
Its overall purpose is to provide one-year seed grants of up to $40,000
to support the work of young research scientists who lack the track
record that is usually necessary to secure major grants from the
National Institutes of Health (NIH).
The IRGP, which is financed entirely by private contributions
to PDF from individuals and was initiated in 1999 with the
help of a matching grant from the Tuchman Foundation, attracts
up to 80 applications every year. The applications are reviewed
by a PDF scientific committee consisting of Parkinson’s
specialists from Columbia University in NYC, Rush Presbyterian-St
Luke’s Medical Center in Chicago and other centers.
The committee judges applications according to the exacting
standards employed by NIH.
The unique mission of IRGP is encapsulated in the word ‘seed’. Its purpose is to support scientists early in their careers in investigating Parkinson’s and thereby to enable them to gather the pilot data that will later lead to larger and long-term financial support from NIH or an international equivalent. In this context, the program acts as a catalyst, leveraging access to major funding. The task of our scientific research committee is, therefore, to seek out these rare pearls that will contribute significantly to our quest for a cure for Parkinson’s.
Dr. Jakowec’s study may move us a step closer to a cure for PD. If surviving dopaminergic neurons can be promoted to restore proper function either through direct intervention or indirectly by influencing other dopaminergic neurons, we will be closer to understanding how the adult brain responds to injury. This knowledge would give insights into the pre-symptomatic phase of PD and potentially result in the development of new therapeutic treatments.











